\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average h	urden									

Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person [*] BOGER JOSHUA S			2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA</u> [VRTX]		tionship of Reporting Pers all applicable) Director Officer (give title	on(s) to Issuer 10% Owner Other (specify
(Last)	(First)	(Middle)			below)	below)
C/O VERTEX PHARMACEUTICALS INCORPORATED		TCALS	3. Date of Earliest Transaction (Month/Day/Year) 05/11/2016			
50 NORTHER	N AVENUE		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Filing	(Check Applicable
(Street)				X	Form filed by One Repo	rting Person
BOSTON	MA	02210			Form filed by More than Person	One Reporting
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	05/11/2016		М		5,130	A	\$35.35	270,414	D	
Common Stock	05/11/2016		S ⁽¹⁾		430	D	\$83.9 ⁽²⁾⁽³⁾	269,984	D	
Common Stock	05/11/2016		S ⁽¹⁾		1,200	D	\$85.26 ⁽²⁾⁽⁴⁾	268,784	D	
Common Stock	05/11/2016		S ⁽¹⁾		1,600	D	\$86.78 ⁽²⁾⁽⁵⁾	267,184	D	
Common Stock	05/11/2016		S ⁽¹⁾		1,400	D	\$87.43(2)(6)	265,784	D	
Common Stock	05/11/2016		S ⁽¹⁾		500	D	\$88.2(2)(7)	265,284	D	
Common Stock								13,286	Ι	401(k)
Common Stock								122,700	Ι	Common Stock Held In Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Expiration		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$35.35	05/11/2016		М			5,130	(8)	07/19/2016	Common Stock	5,130	\$0.00	41,050	D	

Explanation of Responses:

1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

3. Open market sales reported on this line occurred at a weighted average price of \$83.90 (range \$83.60 to \$84.42).

4. Open market sales reported on this line occurred at a weighted average price of \$85.26 (range \$84.76 to \$85.73).

5. Open market sales reported on this line occurred at a weighted average price of \$86.78 (range \$86.11 to \$87.10).

6. Open market sales reported on this line occurred at a weighted average price of \$87.43 (range \$87.13 to \$88.10).

7. Open market sales reported on this line occurred at a weighted average price of \$88.20 (range \$88.14 to \$88.26).

8. Fully vested.

Remarks:

Omar White, Attorney-In-Fact 05/13/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.